Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.
Awaiting Clinical Input
Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.
The Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.
Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.
Low risk secondary myelofibrosis
Intermediate-1 risk secondary myelofibrosis
Intermediate-2 risk secondary myelofibrosis
High risk secondary myelofibrosis
Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.
Open in Web AppClinical Decision Support (CDS) Notice & Legal Disclaimer
This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.